

Author's Accepted Manuscript

Immunotherapy in the Treatment of Urothelial Carcinoma

Nicholas M. Donin , Andrew T. Lenis , Stuart Holden , Alexandra Drakaki , Allan Pantuck , Arie Beldegrun , Karim Chamie



PII: S0022-5347(16)30921-1
DOI: [10.1016/j.juro.2016.02.3005](https://doi.org/10.1016/j.juro.2016.02.3005)
Reference: JURO 13895

To appear in: *The Journal of Urology*
Accepted Date: 20 February 2016

Please cite this article as: Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Beldegrun A, Chamie K, Immunotherapy in the Treatment of Urothelial Carcinoma, *The Journal of Urology*® (2016), doi: 10.1016/j.juro.2016.02.3005.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

Immunotherapy in the Treatment of Urothelial Carcinoma

Nicholas M. Donin MD^{1,3}; Andrew T. Lenis MD¹; Stuart Holden MD^{1,3}; Alexandra Drakaki MD, PhD^{1,2,3,4}; Allan Pantuck MD, MS^{1,2,3}; Arie Belldegrun MD^{1,2,3}; Karim Chamie, MD, MS^{1,2,3}

¹Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA

²Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA

³Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA

⁴Department of Medicine, Division of Hematology & Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA

Corresponding Author:
Karim Chamie MD, MS
Department of Urology
David Geffen School of Medicine
University of California, Los Angeles
300 Stein Plaza, 3rd Floor
Los Angeles, CA 90095
email: kchamie@mednet.ucla.edu

Abstract word count: 339 (350 limit)

Manuscript word count: 4143 (4000 limit)

Keywords: urinary bladder neoplasms; ureteral neoplasms; immunotherapy; BCG vaccine; cancer vaccines; administration, intravesical; cell cycle checkpoints

Runninghead: Immunotherapy in the treatment of urothelial carcinoma

Download English Version:

<https://daneshyari.com/en/article/5686391>

Download Persian Version:

<https://daneshyari.com/article/5686391>

[Daneshyari.com](https://daneshyari.com)